Signal from the log
Expedition Therapeutics
115 M$ · Series B · United States · Biotech
Expedition Therapeutics lève 115 M$ pour s'attaquer à l'inflammation de la bronchopneumopathie chronique obstructive, quatrième cause de mortalité mondiale. Tour mené par General Atlantic.
Article
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 115 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by General Atlantic , with RA Capital , Vivo Capital
Provenance
Logged on 12 August 2026
Description Written in French during the watch run. Based on the headline as relayed by the source, without reading the issuer's press release.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.